GlassScriptPhysician profile
Hui Hu
NPI 1548986276
$18,822.97
in general payments reported to CMS, 2019-2025
24 companies · $7,735 in 2025
The $7,735 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $80.04 · 2023: $5,563 · 2024: $5,445 · 2025: $7,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,556.32 |
| Education | $186.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,976.21 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $1,724.01 | 2023-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $1,588.09 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,391.08 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,370.41 | 2023-2025 | Ingrezza |
| Abbvie INC. | $1,239.69 | 2023-2025 | |
| Alkermes, INC. | $1,183.80 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Vanda Pharmaceuticals INC. | $973.17 | 2023-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $904.36 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $896.52 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $871.54 | 2023-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $870.32 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $757.61 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $734.45 | 2023-2025 | Trintellix |
| Indivior INC. | $354.32 | 2024-2025 | Sublocade |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $341.64 | 2024-2025 | Dyanavel Xr |
| Braeburn INC. | $239.29 | 2025 | Brixadi |
| Idorsia Pharmaceuticals US INC | $168.25 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $95.51 | 2025 | Jornay Pm |
| Uswm, LLC | $41.17 | 2024 | Lucemyra |
| Orexo US, INC. | $35.37 | 2023-2024 | Zubsolv |
| Merck Sharp & Dohme LLC | $32.26 | 2023 | Belsomra |
| Luye Pharma (USA) LTD. | $20.01 | 2025 | Erzofri Extended-Release |
| Bausch Health US, LLC | $13.89 | 2025 | Aplenzin, Wellbutrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.